CO5631431A2 - Indoles sustituidos novedosos - Google Patents

Indoles sustituidos novedosos

Info

Publication number
CO5631431A2
CO5631431A2 CO04120052A CO04120052A CO5631431A2 CO 5631431 A2 CO5631431 A2 CO 5631431A2 CO 04120052 A CO04120052 A CO 04120052A CO 04120052 A CO04120052 A CO 04120052A CO 5631431 A2 CO5631431 A2 CO 5631431A2
Authority
CO
Colombia
Prior art keywords
halogen
optionally substituted
aryl
independently selected
substituents independently
Prior art date
Application number
CO04120052A
Other languages
English (en)
Inventor
Roger Bonnert
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO5631431A2 publication Critical patent/CO5631431A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1.- Un compuesto de fórmula (I) o una sal farmacéuticamente aceptable de este: En dondeR1 es hidrógeno, halógeno, CN, nitro, SO2R4, OH, OR4, S(O)xR4, SO2NR5R6, CO2NR5R6, NR5R6, arilo (opcionalmente sustituido por cloro o flúor), alquenilo C2-C6, alquinilo C2-C6 o alquilo C1-C6, estando los últimos tres grupos opcionalmente sustituidos por uno o más sustituyentes seleccionados independientemente de halógeno, OR8 y NR5R6, S(O)xR7, en donde x es 0, 1 o 2;R2 es hidrógeno, halógeno, CN, SO2R4 o CONR5R6, CH2OH, CH2OR4 o alquilo C1-7, estando el último grupo opcionalmente sustituido por uno o más sustituyentes seleccionados independientemente de átomos de halógeno, OR8 y NR5R6, S(O)xR7, en donde x es 0, 1 o 2;R3 es arilo o heteroarilo cada uno de los cuales está opcionalmente sustituidos por uno o más sustituyentes seleccionados independientemente de hidrógeno, halógeno, CN, nitro, OH, SO2R4, OR4, SR4, SOR4, SO2NR5R6, CONR5R6, NR5R6, NHCOR4, NHSO2R4, NHCO2R4, NR7SO2R4, NR7CO2R4, alquenilo C2-C6, alquinilo C2-C6, alquilo C1-C6, estando los últimos tres grupos opcionalmente sustituidos por uno o más sustituyentes seleccionados independientemente de átomos de halógeno, OR8 y NR5R6, S(O)xR7, en donde x es 0, 1 o 2;R4 representa arilo, heteroarilo o alquilo C1-C6, todos los cuales pueden estar opcionalmente sustituidos por uno o más sustituyentes seleccionados independientemente de átomos de halógeno, arilo, heteroarilo, OR10, OH, NR11R12, S(O)xR13 (en donde x = 0, 1 o 2), CONR14R15, NR14COR15, SO2NR14R15, NR14SO2R15, CN, nitro;R5 y R6 representan independientemente un átomo de hidrógeno, un grupo alquilo C1-C6, o un arilo o un heteroarilo, los últimos tres pueden estar opcionalmente sustituidos por uno o más sustituyentes seleccionados independientemente de átomos de halógeno, arilo, OR8 y NR14R15, CONR14R15, NR14COR15, SO2NR14R15, NR14SO2R15, CN, nitro;oR5 y R6 junto con el átomo de nitrógeno al cual están unidos pueden formar un anillo heterocíclico saturado de 3-8 miembros, ...
CO04120052A 2002-05-30 2004-11-29 Indoles sustituidos novedosos CO5631431A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201635A SE0201635D0 (sv) 2002-05-30 2002-05-30 Novel compounds

Publications (1)

Publication Number Publication Date
CO5631431A2 true CO5631431A2 (es) 2006-04-28

Family

ID=20288018

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04120052A CO5631431A2 (es) 2002-05-30 2004-11-29 Indoles sustituidos novedosos

Country Status (25)

Country Link
US (1) US7166607B2 (es)
EP (1) EP1513812B1 (es)
JP (1) JP4485354B2 (es)
KR (1) KR20050010507A (es)
CN (1) CN100404505C (es)
AR (1) AR039934A1 (es)
AT (1) ATE501118T1 (es)
AU (1) AU2003228201A1 (es)
BR (1) BR0311494A (es)
CA (1) CA2487675A1 (es)
CO (1) CO5631431A2 (es)
DE (1) DE60336314D1 (es)
ES (1) ES2360936T3 (es)
IS (1) IS7607A (es)
MX (1) MXPA04011876A (es)
MY (1) MY133624A (es)
NO (1) NO20045589L (es)
NZ (1) NZ536883A (es)
PL (1) PL375111A1 (es)
RU (1) RU2288914C2 (es)
SE (1) SE0201635D0 (es)
TW (1) TW200407305A (es)
UA (1) UA79464C2 (es)
WO (1) WO2003101961A1 (es)
ZA (1) ZA200409641B (es)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
ES2401079T3 (es) 2002-12-20 2013-04-16 Amgen Inc. Moduladores del asma y de la inflamación alérgica
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) * 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
US20070232681A1 (en) * 2003-10-14 2007-10-04 Oxagen Limited Compounds Having Crth2 Antagonist Activity
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
DK1725553T3 (da) 2004-03-11 2008-08-18 Actelion Pharmaceuticals Ltd Tetrahydropyridoindolderivater
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
WO2005115382A1 (en) 2004-05-29 2005-12-08 7Tm Pharma A/S Crth2 receptor ligands for medicinal uses
GB0412914D0 (en) * 2004-06-10 2004-07-14 Oxagen Ltd Compounds
MY144903A (en) * 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
KR101213912B1 (ko) * 2004-08-26 2012-12-18 액테리온 파마슈티칼 리미티드 Ｃｒｔｈ2 길항제로서의2-설파닐-벤조이미다졸-1-일-아세틱 애시드 유도체
US7405215B2 (en) 2004-09-21 2008-07-29 Wyeth Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof
AU2005302706B2 (en) * 2004-10-27 2011-12-15 Janssen Pharmaceutica N.V. Indole derivatives useful as progesterone receptor modulators
ATE517085T1 (de) 2004-11-23 2011-08-15 Astrazeneca Ab Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
ES2369782T3 (es) 2004-12-27 2011-12-05 Actelion Pharmaceuticals Ltd. Derivados de 2,3,4,9-tetrahidro-1h-carbazol como antagonistas del receptor crth2.
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
WO2007010965A1 (ja) 2005-07-22 2007-01-25 Shionogi & Co., Ltd. Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
JP5072594B2 (ja) * 2005-07-22 2012-11-14 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するインドール誘導体
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
JP5155171B2 (ja) 2005-10-06 2013-02-27 アストラゼネカ・アクチエボラーグ 新規化合物
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
GB0521275D0 (en) * 2005-10-19 2005-11-30 Argenta Discovery Ltd 3-Aminoindole compounds
GB0524428D0 (en) 2005-11-30 2006-01-11 7Tm Pharma As Medicinal use of receptor ligands
GB0525143D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
CN101454284A (zh) 2006-05-26 2009-06-10 阿斯利康(瑞典)有限公司 联芳基或芳基-杂芳基取代的吲哚类化合物
DK2037967T3 (en) 2006-06-16 2017-03-13 Univ Pennsylvania PROSTAGLANDIN-D2 RECEPTOR ANTAGONISTS FOR TREATMENT OF ANDROGENETIC ALOPECI
EP2046740B1 (en) 2006-07-22 2012-05-23 Oxagen Limited Compounds having crth2 antagonist activity
KR101411820B1 (ko) 2006-08-07 2014-06-24 액테리온 파마슈티칼 리미티드 (3-아미노-1,2,3,4-테트라하이드로-9ｈ-카르바졸-9-일)-아세트산 유도체
JP2010522149A (ja) * 2007-03-21 2010-07-01 アージェンタ オーラル セラピューティクス リミテッド Ｃｒｔｈ２アンタゴニストとしてのインドリジン酢酸誘導体
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
EP2229358B1 (en) 2007-12-14 2011-03-23 Pulmagen Therapeutics (Asthma) Limited Indoles and their therapeutic use
BRPI0821197A2 (pt) 2007-12-19 2015-06-16 Amgen Inc Composto, composição farmacêutica, uso de um composto, processo, e, intermediário.
PT2250161E (pt) 2008-01-18 2014-01-21 Atopix Therapeutics Ltd Compostos tendo atividade antagonista de crth2
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
JP2011509990A (ja) 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
EP2240444A1 (en) 2008-01-22 2010-10-20 Oxagen Limited Compounds having crth2 antagonist activity
WO2011055270A1 (en) 2009-11-04 2011-05-12 Wyeth Llc Indole based receptor crth2 antagonists
UY33110A (es) 2009-12-23 2011-07-29 Ironwood Pharmaceuticals Inc Moduladores de CRTH2
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
BR112012024114B1 (pt) 2010-03-22 2021-02-09 Idorsia Pharmaceuticals Ltd Compostos derivados de 3-(heteroarilamino)-1,2,3,4-tetrahidro-9h-carbazol, uso dos mesmos, e, composição farmacêutica
BR112012033341B1 (pt) 2010-06-30 2022-08-23 Cyclerion Therapeutics, Inc Estimulantes de sgc
US20130259830A1 (en) 2010-07-12 2013-10-03 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009137A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
US9061030B2 (en) 2010-11-09 2015-06-23 Ironwood Pharmaceuticals, Inc. sGC stimulators
AU2012241442B2 (en) 2011-04-14 2017-01-12 Idorsia Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido(1,2-a)indol acetic acid derivatives and their use as prostaglandin D2 receptor modulators
EP2710119A4 (en) * 2011-05-17 2015-02-18 Cleave Biosciences Inc COMPOSITION AND METHODS FOR INHIBITION OF JAMM PROTEINS
MX2014007239A (es) 2011-12-16 2014-08-08 Atopix Therapeutics Ltd Combinacion de un antagonista crth2 y un inhibidor de bomba de proton para el tratamiento de esofagitis eosinofilica.
KR101939710B1 (ko) 2011-12-21 2019-01-17 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
EP2797915B1 (en) 2011-12-27 2016-07-13 Ironwood Pharmaceuticals, Inc. 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure
CN104602763B (zh) 2012-03-21 2018-08-21 宾夕法尼亚大学理事会 用于调节毛发生长的组合物和方法
KR20210081451A (ko) 2012-08-28 2021-07-01 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도
UA115069C2 (uk) * 2012-08-28 2017-09-11 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Конденсовані біциклічні похідні сульфамоїлу та їх застосування як лікарських препаратів для лікування гепатиту b
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
CA2885645A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2014131847A1 (en) 2013-02-28 2014-09-04 Janssen R&D Ireland Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
LT2970243T (lt) 2013-03-15 2020-03-10 Cyclerion Therapeutics, Inc. Sgc stimuliatoriai
PT2981536T (pt) 2013-04-03 2017-08-09 Janssen Sciences Ireland Uc Derivados de n-fenil-carboxamida e sua utilização como medicamentos para o tratamento da hepatite b
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
WO2015011281A1 (en) 2013-07-25 2015-01-29 Janssen R&D Ireland Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
DK3060547T3 (en) 2013-10-23 2018-01-15 Janssen Sciences Ireland Uc CARBOXAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATMENT OF HEPATITS B
EP3092231B1 (en) 2013-12-11 2018-06-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
EP3094327A1 (en) 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
CA2936947A1 (en) 2014-02-05 2015-08-13 Novira Therapeutics, Inc. Combination therapy for treatment of hbv infections
US11078193B2 (en) 2014-02-06 2021-08-03 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
LT3119779T (lt) 2014-03-17 2018-09-10 Idorsia Pharmaceuticals Ltd Azaindolo acto rūgšties dariniai ir jų panaudojimas kaip prostaglandino d2 receptoriaus moduliatorių
TW201620909A (zh) 2014-03-18 2016-06-16 艾克泰聯製藥有限公司 氮雜吲哚乙酸衍生物及彼等作為前列腺素ｄ２受體調節劑之用途
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
TWI695831B (zh) * 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Ｃｒｔｈ２拮抗劑化合物及其用途
WO2016044445A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
US10844064B2 (en) 2014-09-17 2020-11-24 Cyclerion Therapeutics, Inc. sGC stimulators
US20170291889A1 (en) 2014-09-17 2017-10-12 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
JP2018510159A (ja) 2015-03-19 2018-04-12 ノヴィラ・セラピューティクス・インコーポレイテッド アゾカン及びアゾナン誘導体及びｂ型肝炎感染症の治療法
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CN108472510A (zh) 2015-07-30 2018-08-31 宾夕法尼亚大学理事会 用于检测pgd2对毛发生长抑制的易感性的人dp-2基因的单核苷酸多态性等位基因
MX2018003202A (es) 2015-09-15 2018-06-08 Idorsia Pharmaceuticals Ltd Formas cristalinas.
JP6845231B2 (ja) 2015-09-29 2021-03-17 ノヴィラ・セラピューティクス・インコーポレイテッド Ｂ型肝炎抗ウイルス薬の結晶形態
JP2019511542A (ja) 2016-04-15 2019-04-25 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カプシド集合阻害剤を含む組み合わせ及び方法
IL263996B2 (en) 2016-07-07 2024-03-01 Ironwood Pharmaceuticals Inc Solid configurations of the SGC promoter
WO2018009596A1 (en) 2016-07-07 2018-01-11 Ironwood Pharmaceuticals, Inc. Phosphorus prodrugs of sgc stimulators
AU2019235522A1 (en) 2018-03-14 2020-09-03 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
US11096931B2 (en) 2019-02-22 2021-08-24 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
AU2020269897A1 (en) 2019-05-06 2021-10-14 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
WO2022166638A1 (zh) * 2021-02-02 2022-08-11 广东东阳光药业有限公司 吲哚衍生物的盐及其用途
CN115093360B (zh) * 2022-07-06 2023-11-17 都创(上海)医药科技股份有限公司 一种吲哚类衍生物的合成方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) * 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPS5239671A (en) * 1975-09-22 1977-03-28 Sankyo Co Ltd Process for preparing indole-3-thioether compounds
US5095031A (en) * 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
WO1993005020A1 (en) 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase
FR2692574B1 (fr) * 1992-06-23 1995-06-23 Sanofi Elf Derives hydroxy-4 benzenethio, leur preparation ainsi que leur utilisation pour la preparation de derives aminoalkoxybenzenesulfonyles.
AU6165894A (en) 1993-01-28 1994-08-15 Trustees Of The University Of Pennsylvania, The Use of creatine or analogs for the manufacture of a medicament for inhibiting tumor growth
BR9405737A (pt) 1993-02-24 1995-12-05 Merck & Co Inc Composto processo de inibição de transcriptase reserva de HIV, processo de prevenção contra a infecção pelo HIV ou de tratamento da infecção pelo HIV, composição farmacêutica útil para a inibição da transcriptase reserva de HIV, e, útil para a prevenção ou tratamento de infecção pelo HIV ou para o tratamento da AIDS ou ARC
US5486525A (en) * 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5567711A (en) * 1995-04-19 1996-10-22 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
WO1999009007A1 (en) 1997-08-21 1999-02-25 American Home Products Corporation Solid phase synthesis of 2,3-disubstituted indole compounds
DK0924209T3 (da) 1997-12-19 2003-08-25 Lilly Co Eli Hypoglykæmiske imidazolinforbindelser
WO2000078761A1 (en) 1999-06-23 2000-12-28 Sepracor, Inc. Indolyl-benzimidazole antibacterials, and methods of use thereof
AU7962200A (en) 1999-10-29 2001-05-14 Wakunaga Pharmaceutical Co., Ltd Novel indole derivatives and drugs containing the same as the active ingredient
CN100379734C (zh) 1999-12-24 2008-04-09 阿文蒂斯药物有限公司 氮杂吲哚类化合物
MXPA02011770A (es) 2000-05-31 2003-04-10 Astrazeneca Ab Derivados de indol con actividad de dano vascular.
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
EP1501826B1 (en) 2002-02-01 2006-09-27 F. Hoffman-la Roche AG Substituted indoles as alpha-1 agonists
WO2003097598A1 (fr) 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Composé comprenant un antagonisme du récepteur de pdg2
TW200307542A (en) * 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
US7166607B2 (en) 2007-01-23
NZ536883A (en) 2006-08-31
RU2004135064A (ru) 2005-08-10
CA2487675A1 (en) 2003-12-11
DE60336314D1 (de) 2011-04-21
IS7607A (is) 2004-12-21
NO20045589L (no) 2005-02-02
UA79464C2 (en) 2007-06-25
WO2003101961A1 (en) 2003-12-11
RU2288914C2 (ru) 2006-12-10
CN100404505C (zh) 2008-07-23
TW200407305A (en) 2004-05-16
EP1513812A1 (en) 2005-03-16
ZA200409641B (en) 2006-02-22
JP2005538955A (ja) 2005-12-22
MY133624A (en) 2007-11-30
EP1513812B1 (en) 2011-03-09
CN1671659A (zh) 2005-09-21
MXPA04011876A (es) 2005-03-31
AR039934A1 (es) 2005-03-09
ES2360936T3 (es) 2011-06-10
JP4485354B2 (ja) 2010-06-23
US20050165055A1 (en) 2005-07-28
PL375111A1 (en) 2005-11-28
ATE501118T1 (de) 2011-03-15
AU2003228201A1 (en) 2003-12-19
SE0201635D0 (sv) 2002-05-30
BR0311494A (pt) 2005-03-29
KR20050010507A (ko) 2005-01-27

Similar Documents

Publication Publication Date Title
CO5631431A2 (es) Indoles sustituidos novedosos
CO5630030A2 (es) Acido 4-(acetilamino)-3-{(4-clorofenil)tio}-2-metil-1h-indol-1-acetico y composicion farmaceutica que lo contiene
AR039933A1 (es) Indoles sustituidos para tratamiento de desordenes respiratorios
AR045462A1 (es) DERIVADOS DE INDOLES SUSTITUIDOS eTILES COMO COMPUESTOS FARMACEUTICOS PARA EL TRATAMIENTO DE ENFERMEDADES RESPIRATORIAS
ES2525763T3 (es) Derivados del ácido fenilalcanoico sustituido y sus usos para el tratamiento de enfermedades respiratorias
CO5580746A2 (es) Derivados de fenil-piperazina como inhibidores de la reabsorcion de la serotonina
CO5680430A2 (es) Derivados de 1-benzol-piperazina como inhibidores de la captacion de glicina para el ratamiento de psicosis
DK0534707T3 (da) alkoxysubstituerede taxaner som antitumormidler
DK0534708T3 (da) Furyl- og thienylsubstituerede taxaner som antitumormidler
CY1110216T1 (el) Παραγωγα αρυλαλκυλκαρβαμικων, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη αγωγη
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
AR041661A1 (es) Compuestos triciclicos utiles para el tratamiento de desordenes inflamatorios y alergicos procesos para su preparacion y composiciones farmaceuticas que lo contienen
KR950703547A (ko) 탁산 유도체의 제조방법(method of preparing taxane derivatives)
CY1107978T1 (el) Νeα παρaγωγα πυριδαζiν -3 (2h) - oνης
DK1117297T3 (da) Syntetiske analoger af ecteinascidin-743
PE20080068A1 (es) Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
PA8568301A1 (es) Derivados de aminoindazoles, procedimiento de preparacion e intermedios de este procedimiento a titulo de medicamentos y composiciones farmaceuticas que los contienen.
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
CO5690598A2 (es) 6-[(sustituido)fenil]triazolopirimidinas como agentes anticancer
CO5261622A1 (es) Inhibidores de la proteinasa c del procolageno
EA200000400A1 (ru) Галогензамещенные тетрациклические производные тетрагидрофурана
CO5590924A2 (es) Derivados de indolilalquilamina como ligandos de 5- hidroxitriptamina-6
AR059032A1 (es) Combinacion de derivados de triazina y sensibilizadores de insulina
CO4990960A1 (es) Derivados de cetolidos 2-halo-6-o sustituidos
ATE409180T1 (de) Synthese von zyklopentadien derivaten

Legal Events

Date Code Title Description
FC Application refused